A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Exclusion Criteria

• •1. Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL, or of transformed FL
• •2. WHO subclassification of duodenal-type FL
• •3. Central nervous system-only involvement by malignancy (subjects with secondary central nervous system (CNS) involvement are allowed on study)
• •4. History of another primary malignancy that has not been in remission for at least 2 years, with the exception of non-invasive malignancies
• •5. Prior CAR T-cell or other genetically-modified cell therapy
• •6. History of or active human immunodeficiency virus (HIV)
• •7. Active hepatitis B or active hepatitis C
• •8. Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment
• •9. Active autoimmune disease requiring immunosuppressive therapy
• •10. Presence of acute or chronic graft-versus-host=disease
• •11. History of significant cardiovascular disease
• •12. History or presence of clinically relevant central nervous system pathology
• •13. Allogenic-hematopoietic stem cell transplant (Allo-HSCT) within 90 days of leukapheresis